Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
$1.99
per week
for 24 weeks
Start Today
// //
Subscribe from $1.99/WK
Register
AdChoices

Amgen Inc NASDAQ: AMGN-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time
Alerts Watchlist Portfolio

Today's Trading

Day Low 238.37
Day High 242.48
Open:242.12
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
number cruncher
Nine U.S. health care stocks showing fair valuations, earnings growth
Subscriber content
number cruncher
Thirteen stocks to watch in resurgent U.S. health care sector
Subscriber content
number cruncher
Twelve U.S. dividend growth stocks that provide stable income
Subscriber content
inside the market
Market movers: Stocks that saw action on Monday - and why
Subscriber content
inside the market
What every Canadian investor needs to know today
Subscriber content
globe investor
Salesforce to replace Exxon in Dow Jones Industrial Average index next week
Description
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy
View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
Amgen Announces 2021 Third Quarter Dividend
- PR Newswire - PRF - Fri Jul 30, 3:00PM CDT
PR Newswire - PRF - CMTX
Fri Jul 30, 3:00PM CDT
July 30, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a per share dividend for the third quarter of 2021. The dividend will be paid on , to all stockholders of record as of the close of business on .
Amgen Appoints S. Omar Ishrak To Board Of Directors
- PR Newswire - PRF - Thu Jul 29, 6:10PM CDT
PR Newswire - PRF - CMTX
Thu Jul 29, 6:10PM CDT
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately.  Dr. Ishrak will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Compensation and Management Development Committee, effective , 2021.  Following the appointment of Dr. Ishrak, the Board will be composed of 12 directors, 11 of whom are independent.
Amgen Announces Webcast Of 2021 Second Quarter Financial Results
- PR Newswire - PRF - Thu Jul 29, 3:00PM CDT
PR Newswire - PRF - CMTX
Thu Jul 29, 3:00PM CDT
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at . Participating in the call from Amgen will be , chairman and chief executive officer, and other members of Amgen's senior management team.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 238.37 +0.60% increase
on 08/02/21
Period Open:248.70
Price movement based on the high, low and last over the given period.
250.39 -4.23% decrease
on 07/20/21
 -8.91 (-3.58%) decrease
since 07/02/21
3-Month 232.94 +2.94% increase
on 06/01/21
Period Open:239.64
Price movement based on the high, low and last over the given period.
258.81 -7.35% decrease
on 05/10/21
 +0.15 (+0.06%) increase
since 04/30/21
52-Week 210.28 +14.03% increase
on 10/29/20
Period Open:244.67
Price movement based on the high, low and last over the given period.
276.69 -13.34% decrease
on 01/28/21
 -4.88 (-1.99%) decrease
since 07/31/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies